Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma
the ONA take:
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for patients with aggressive renal cell carcinoma (RCC), a recent study published in the journal Cancer has shown.
Because no standard treatment exists for patients with sarcomatoid RCC, a type of kidney cancer associated with an aggressive biology and a poor prognosis, and treatment options for patients with poor-risk disease provide minimal benefit, researchers sought to evaluate the efficacy and safety of antiangiogenic therapy in combination with cytotoxic therapy in clinically aggressive RCC.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with sarcomatoid RCC and 33 with poor-risk RCC. All patients received sunitinib plus gemcitabine.
Results showed that the objective response rate was 26% and 24% for patients with sarcomatoid RCC and poor-risk RCC, respectively.
The median time to progression was 5 months for patients with sarcomatoid RCC and 5.5 months for those with poor-risk RCC. Median overall survival was 10 months and 15 months, respectively.
In regard to safety, the most common grade 3 or higher treatment-associated adverse events were neutropenia, anemia, and fatigue.
“The combination may be more efficacious than either therapy alone and is currently under further investigation,” the authors conclude.
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|